Pro­tara's $45M place­ment; Plus, news about Eu­prax­ia and Gen­Sight

Pro­tara Ther­a­peu­tics rais­es $45M pri­vate place­ment: The over­sub­scribed fi­nanc­ing trans­ac­tion is set to close April 10. The pro­ceeds should ex­tend the com­pa­ny’s run­way through 2026 and help fund an on­go­ing Phase 2 tri­al of TARA-002 in high-risk non-mus­cle in­va­sive blad­der can­cer. — Ay­isha Shar­ma

Eu­prax­ia Phar­ma­ceu­ti­cals makes Nas­daq de­but: The Cana­di­an com­pa­ny, which fo­cus­es on de­vel­op­ing treat­ments for in­flam­ma­to­ry joint con­di­tions and can­cer, is now trad­ing un­der the tick­er $EPRX. Eu­prax­ia is us­ing its so-called Dif­fu­sphere tech­nol­o­gy to en­able tar­get­ed de­liv­ery of ac­tive in­gre­di­ents with ex­tend­ed ef­fect du­ra­tion and “tun­able” PK pro­files. — Ay­isha Shar­ma

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER